A Novel Liposome-Based Adjuvant CAF01 for Induction of CD8 + Cytotoxic T-Lymphocytes (CTL) to HIV-1 Minimal CTL Peptides in HLA-A*0201 Transgenic Mice

Gregers Jacob Gram, Ingrid Karlsson, Else Marie Agger et al. · 2009

Read A Novel Liposome-Based Adjuvant CAF01 for Induction of CD8 + Cytotoxic T-Lymphocytes (CTL) to HIV-1 Minimal CTL Peptides in HLA-A*0201 Transgenic Mice by Gregers Jacob Gram, Ingrid Karlsson, Else Marie Agger et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0006950.txt.

Description

Gregers Gram, Ingrid Karlsson, Else Marie Agger, and colleagues tested a vaccine adjuvant in PLOS ONE in 2009. Strong killer T cell responses are a prized feature of viral vaccines. Adjuvants are the helper ingredients that can coax such responses out. The team studied a new liposome-based adjuvant called CAF01.

They paired CAF01 with very small HIV-1 peptide antigens. Tests ran in transgenic mice carrying a human immune gene, HLA-A*0201. The goal was to raise CD8 cytotoxic T lymphocytes against those peptides. A working adjuvant of this kind could strengthen future HIV vaccine designs that rely on killer T cells.

Catalog record

CREATORGregers Jacob Gram, Ingrid Karlsson, Else Marie Agger et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE21 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0006950

Browse the full library · About the Tower of Babel